Revised SPC: Dupixent (dupilumab) solution for injection – all presentations and strengths

SPC now advises patients with atopic dermatitis or chronic rhinosinusitis with nasal polyps who also have comorbid asthma should not adjust or stop their asthma treatments without consultation with physicians & should be monitored carefully following discontinuation of dupilumab.

SPS commentary:

SPC also warns that cases of eosinophilic pneumonia and vasculitis consistent with eosinophilic granulomatosis with polyangiitis (EGPA) have been reported with dupilumab in adult patients who participated in the asthma development program.

electronic Medicines compendium